ReviewPediatric nephrology (Berlin, Germany)2021
Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.
Review in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- 2025 KDIGO Executive Summary: Diagnosis and Management of Pediatric Autosomal Dominant Polycystic Kidney Disease.Kidney & blood pressure research · 2026Guideline
- A cross-model single-cell atlas reveals conserved involvement of osteopontin in polycystic kidney disease.JCI insight · 2026Article
- Macroscopic hematuria in children with autosomal dominant polycystic kidney disease - report from four European tertiary centers.European journal of pediatrics · 2026Article
- Predictors of kidney survival in children with autosomal recessive polycystic kidney disease.Clinical and experimental nephrology · 2026Article
- Autosomal dominant polycystic kidney disease in children and adolescents.Childhood kidney diseases · 2026Review
- Novel compound heterozygousFrontiers in medicine · 2026Article
- Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.Renal failure · 2025Review
- Article
- A cross model spatial and single-cell atlas reveals the conserved involvement of osteopontin in polycystic kidney disease.bioRxiv : the preprint server for biology · 2025Article
- Heart dysfunction in a rat model with autosomal recessive polycystic kidney disease.The Journal of physiology · 2025Article
- Multimodal Magnetic Resonance Imaging Assessments of Kidney Disease Severity in Autosomal Recessive Polycystic Kidney Disease.Kidney international reports · 2024Article
- Genetic landscape and clinical outcomes of autosomal recessive polycystic kidney disease in Kuwait.Heliyon · 2024Article
- How Does ADPKD Severity Differ Between Family Members?Kidney international reports · 2024Review
- Defects of renal tubular homeostasis and cystogenesis in theiScience · 2024Article
- Pathogenic relationship between phenotypes of ARPKD and novel compound heterozygous mutations ofFrontiers in genetics · 2024Article
- Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?Clinical journal of the American Society of Nephrology : CJASN · 2023Article
- Case report: Genotype-phenotype characteristics of nine novelFrontiers in medicine · 2023Article
- A 7-year-old girl with renal medullary hyperechogenicity and hypertension: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- Molecular Pathophysiology of Autosomal Recessive Polycystic Kidney Disease.International journal of molecular sciences · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are characterized by bilateral cystic kidney disease leading to progressive kidney function decline. These diseases also have distinct liver manifestations. The range of clinical presentation and severity of both ADPKD and ARPKD is much wider than was once recognized. Pediatric and adult nephrologists are likely to care for individuals with both diseases in their lifetimes. This article will review genetic, clinical, and imaging predictors of kidney and liver disease progression in ADPKD and ARPKD and will briefly summarize pharmacologic therapies to prevent progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.